ESMO 2020: Results of a phase II study examining nivolumab combined with brentuximab vedotin for treatment of relapsed Hodgkin lymphoma.
Home / Resource Library / 903P Combination of nivolumab with brentuximab vedotin in therapy of relapsed and refractory Hodgkin lymphoma